1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

14 Mar 2024
Admin
News Article

Arecor & TRx BioSciences Partners for Oral GLP-1 Therapy

Arecor and TRx BioSciences Establish Partnership for Advancing Oral GLP-1 Therapy with Improved Bioavailability

Arecor Therapeutics plc (AIM: AREC), a biopharmaceutical company focused on advancing modern therapies for improved health outcomes, has teamed up with TRx Biosciences Limited, a leader in innovative lipid technology for oral drug delivery. Together, they have announced a research collaboration aimed at formulating an oral glucagon-like peptide-1 (GLP-1) receptor agonist product.

GLP-1 Receptor Agonists: Funds & Challanges

GLP-1 receptor agonists are crucial for managing type 2 diabetes and obesity.
The global market for these treatments is projected to reach $80-$100+ billion by 2030.
However, delivering these drugs orally presents significant challenges due to the digestive system's proteolytic nature, resulting in reduced bioavailability.
Currently, injection remains the primary delivery method, limiting patient adoption, compliance, and usage.
Aim for thi collaboration
The only oral GLP-1 receptor agonist available to patients is Novo Nordisk’s semaglutide (Rybelsus®), which boasts less than 1% oral bioavailability.
To address this issue, Arecor and TRx Biosciences plan to utilize TRx Biosciences’ LipiCore™ oral delivery technology along with Arecor’s formulation platform, Arestat™.
This collaboration aims to develop an oral GLP-1 receptor agonist product with improved physicochemical properties to achieve higher oral bioavailability and stability.

Arecor CEO on Challanges

Sarah Howell, CEO of Arecor, highlighted the ongoing challenges in oral delivery for GLP-1 receptor agonists and expressed optimism in leveraging Arecor's Arestat™ technology alongside TRx Biosciences' expertise to develop an enhanced oral product.
Dr. Robin Bannister, CEO of TRx Biosciences, emphasized the importance of effective oral peptide delivery and the potential of combining LipiCore™ with Arecor's platform to unlock novel oral uptake channels and protect peptides during gastrointestinal transit.

Novel GLP-1 Receptor Agonist

The collaboration aims to extend beyond the initial GLP-1 receptor agonist program to develop additional oral peptide products, potentially targeting obesity-related health conditions and other therapeutic areas.
Success in this endeavor could revolutionize oral peptide therapy, providing patients with more convenient and effective treatment options.